The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
APOE ε4 lowers age at onset and is a high risk factor for Alzheimer's disease; A case control study from central Norway
Open accessAbstract
BACKGROUND: The objective of this study was to analyze factors influencing the risk and timing of Alzheimer's disease (AD) in central Norway. The APOE epsilon4 allele is the only consistently identified risk factor for late onset Alzheimer's disease (LOAD). We have described the allele frequencies of the apolipoprotein E gene (APOE) in a large population of patients with AD compared to the frequencies in a cognitively-normal control group, and estimated the effect of the APOE epsilon4 allele on the risk and the age at onset of AD in this population. METHODS: 376 patients diagnosed with AD and 561 cognitively-normal control individuals with no known first degree relatives with dementia were genotyped for the APOE alleles. Allele frequencies and genotypes in patients and control individuals were compared. Odds Ratio for developing AD in different genotypes was calculated. RESULTS: Odds Ratio (OR) for developing AD was significantly increased in carriers of the APOE epsilon4 allele compared to individuals with the APOE epsilon3/epsilon3 genotype. Individuals carrying APOE epsilon4/epsilon4 had OR of 12.9 for developing AD, while carriers of APOE epsilon2/epsilon4 and APOE epsilon3/epsilon4 had OR of 3.2 and 4.2 respectively. The effect of the APOE epsilon4 allele was weaker with increasing age. Carrying the APOE epsilon2 allele showed no significant protective effect against AD and did not influence age at onset of the disease. Onset in LOAD patients was significantly reduced in a dose dependent manner from 78.4 years in patients without the APOE epsilon4 allele, to 75.3 in carriers of one APOE epsilon4 allele and 72.9 in carriers of two APOE epsilon4 alleles. Age at onset in early onset AD (EOAD) was not influenced by APOE epsilon4 alleles. CONCLUSION: APOE epsilon4 is a very strong risk factor for AD in the population of central Norway, and lowers age at onset of LOAD significantly.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“as well as an earlier age of onset for developing the disease (approximately 5 years for each APOE4 allele compared to APOE3 homozygotes).6,9,10”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE4 homozygotes have a markedly increased risk of developing AD (14.5-fold compared to APOE3 homozygotes)”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Each ApoE4 allele reduces the age of Alzheimer’s disease (AD) onset by approximately 3–5 years compared to ApoE3 homozygotes, which comprise ~80% of the human population (Roses, 1994; Sando et al., 2008).”
From NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load (2021) · cites this paper as Sando et al., 2008
Experimental — accuracy not yet measuredIn the citing paper
“Each ApoE4 allele reduces the age of Alzheimer’s disease (AD) onset by approximately 3–5 years compared to ApoE3 homozygotes, which comprise ~80% of the human population (Roses, 1994; Sando et al., 2008).”
From NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load (2021) · cites this paper as Sando et al., 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Apolipoprotein E polymorphism and Alzheimer's disease
Poirier, J., Bertrand, P., Poirier, J., Kogan, S., Gauthier, S., Poirier, J., Gauthier, S., Davignon, J., Bouthillier, D., & Davignon, J. (1993) · The Lancet · doi:10.1016/0140-6736(93)91705-q · Cited by 1,108
Ott, A., Breteler, M. M. B., van Harskamp, F., Claus, J. J., van der Cammen, T. J. M., Grobbee, D. E., & Hofman, A. (1995) · BMJ · doi:10.1136/bmj.310.6985.970 · Cited by 792
Rates and risk factors for dementia and Alzheimer’s disease: Results from EURODEM pooled analyses
Launer, L. J., Andersen, K., Dewey, M. E., Letenneur, L., Ott, A., Amaducci, L. A., Brayne, C., Copeland, J. R. M., Dartigues, J.-F., Kragh-Sorensen, P., et al. (1999) · Neurology · doi:10.1212/wnl.52.1.78 · Cited by 758
Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a ‘thrifty’ allele?
Corbo, R. M., & Scacchi, R. (1999) · Annals of Human Genetics · doi:10.1046/j.1469-1809.1999.6340301.x · Cited by 653
Cited by
Sorted by citations
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0228-7 · Cited by 1,425
Cooper, D. N., Krawczak, M., Polychronakos, C., Tyler‐Smith, C., & Kehrer‐Sawatzki, H. (2013) · Human Genetics · doi:10.1007/s00439-013-1331-2 · Cited by 671
Topical capsaicin (high concentration) for chronic neuropathic pain in adults
Derry, S., Rice, A. S. C., Cole, P., Tan, T., & Moore, A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007393.pub4 · Cited by 569
Prevalencia e incidencia de la enfermedad de Alzheimer en Europa: metaanálisis
Niu, H., Álvarez‐Álvarez, I., Guillén‐Grima, F., & Aguinaga-Ontoso, I. (2016) · Neurología · doi:10.1016/j.nrl.2016.02.016 · Cited by 466
ApoE Cascade Hypothesis in the pathogenesis of Alzheimer’s disease and related dementias
Martens, Y. A., Zhao, N., Liu, C.-C., Kanekiyo, T., Yang, A. J., Goate, A. M., Holtzman, D. M., & Bu, G. (2022) · Neuron · doi:10.1016/j.neuron.2022.03.004 · Cited by 316
Prevalence and incidence of Alzheimer's disease in Europe: A meta-analysis
Niu, H., Álvarez-Álvarez, I., Guillén‐Grima, F., & Aguinaga-Ontoso, I. (2017) · Neurología (English Edition) · doi:10.1016/j.nrleng.2016.02.009 · Cited by 333
Fernández-Calle, R., Konings, S. C., Frontiñán-Rubio, J., García-Revilla, J., Camprubí-Ferrer, L., Svensson, M., Martinson, I., Boza-Serrano, A., Venero, J. L., Nielsen, H. M., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00566-4 · Cited by 278
Fernandez, C. G., Hamby, M. E., McReynolds, M. L., & Ray, W. J. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00014 · Cited by 277
Shoemark, D. K., & Allen, S. J. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141170 · Cited by 251
Tolar, M., Hey, J., Power, A., & Abushakra, S. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126355 · Cited by 253
Higher Rates of Decline for Women and Apolipoprotein E ε4 Carriers
Holland, D., Desikan, R. S., Dale, A. M., & McEvoy, L. K. (2013) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3601 · Cited by 219
Uddin, M. S., Kabir, M. T., Al Mamun, A., Abdel-Daim, M. M., Barreto, G. E., & Ashraf, G. M. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1237-z · Cited by 212
Comorbidity of periodontal disease: two sides of the same coin? An introduction for the clinician
Holmstrup, P., Damgaard, C., Olsen, I., Klinge, B., Flyvbjerg, A., Nielsen, C. H., & Hansen, P. R. (2017) · Journal of Oral Microbiology · doi:10.1080/20002297.2017.1332710 · Cited by 214
DiLoreto, R., & Murphy, C. T. (2015) · Molecular Biology of the Cell · doi:10.1091/mbc.e14-06-1084 · Cited by 192
Can oral infection be a risk factor for Alzheimer's disease?
Olsen, I., & Singhrao, S. K. (2015) · Journal of Oral Microbiology · doi:10.3402/jom.v7.29143 · Cited by 192
APOE genotype and cognition in healthy individuals at risk of Alzheimer's disease: A review
O'Donoghue, M. C., Murphy, S. E., Zamboni, G., Nobre, A. C., & Mackay, C. E. (2018) · Cortex · doi:10.1016/j.cortex.2018.03.025 · Cited by 191
Plasma biomarkers for mild cognitive impairment and Alzheimer's disease
Song, F., Poljak, A., Smythe, G. A., & Sachdev, P. S. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.05.003 · Cited by 181
AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease
Rosenberg, J. B., Kaplitt, M. G., De, B. P., Chen, A., Flagiello, T., Salami, C., Pey, E., Zhao, L., Ricart Arbona, R. J., Monette, S., et al. (2018) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.231 · Cited by 176
Yamazaki, Y., Painter, M. M., Bu, G., & Kanekiyo, T. (2016) · CNS Drugs · doi:10.1007/s40263-016-0361-4 · Cited by 173
Freitas, C., Mondragón-Llorca, H., & Pascual‐Leone, Á. (2011) · Experimental Gerontology · doi:10.1016/j.exger.2011.04.001 · Cited by 170
Arora, S., Layek, B., & Singh, J. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00461 · Cited by 149
Mueller, S. G., Chao, L. L., Berman, B. D., & Weiner, M. W. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.03.028 · Cited by 156
Blom, E. S., Giedraitis, V., Zetterberg, H., Fukumoto, H., Blennow, K., Hyman, B. T., Irizarry, M. C., Wahlund, L., Lannfelt, L., & Ingelsson, M. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000216841 · Cited by 141
ApoE4 and Aβ Oligomers Reduce BDNF Expression via HDAC Nuclear Translocation
Sen, A., Nelson, T. J., & Alkon, D. L. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.0260-15.2015 · Cited by 133
An exhausted-like microglial population accumulates in aged and APOE4 genotype Alzheimer’s brains
Millet, A., Ledo, J. H., & Tavazoie, S. F. (2024) · Immunity · doi:10.1016/j.immuni.2023.12.001 · Cited by 132
Exercise, APOE genotype, and the evolution of the human lifespan
Raichlen, D. A., & Alexander, G. E. (2014) · Trends in Neurosciences · doi:10.1016/j.tins.2014.03.001 · Cited by 132
Morphine for chronic neuropathic pain in adults
Cooper, T. E., Chen, J., Wiffen, P. J., Derry, S., Carr, D. B., Aldington, D. J., Cole, P., & Moore, R. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011669.pub2 · Cited by 128
Examination of the current top candidate genes for AD in a genome-wide association study
Feulner, T. M., Laws, S. M., Friedrich, P., Wagenpfeil, S., Wurst, S. H. R., Riehle, C., Kuhn, K. A., Krawczak, M., Schreiber, S., Nikolaus, S., et al. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.141 · Cited by 128
Telomere Shortening and Alzheimer’s Disease
Cai, Z., Yan, L., & Ratka, A. (2012) · NeuroMolecular Medicine · doi:10.1007/s12017-012-8207-9 · Cited by 121
The cell biology of APOE in the brain
Windham, I. A., & Cohen, S. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.09.004 · Cited by 103
Han, M.-R., Schellenberg, G. D., Wang, L.-S., & Initiative, T. A. D. N. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-90 · Cited by 93
Allen, M., Zou, F., Chai, H. S., Younkin, C. S., Miles, R., Nair, A., Crook, J. E., Pankratz, V. S., Carrasquillo, M. M., Rowley, C. N., et al. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-13 · Cited by 93
Self-citationAge-related differences in white matter integrity and cognitive function are related to APOE status
Ryan, L., Walther, K., Bendlin, B. B., Lue, L., Walker, D. G., & Glisky, E. L. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.08.052 · Cited by 91
Gao, F., Lv, X., Dai, L., Wang, Q., Wang, P., Cheng, Z., Xie, Q., Ni, M., Wu, Y., Chai, X., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12700 · Cited by 91
Apolipoprotein E gene polymorphism and Alzheimer's disease in Chinese population: a meta-analysis
Liu, M., Bian, C., Zhang, J., & Wen, F. (2014) · Scientific Reports · doi:10.1038/srep04383 · Cited by 72
ApoE variant p.V236E is associated with markedly reduced risk of Alzheimer’s disease
Medway, C. W., Abdul-Hay, S., Mims, T., Ma, L., Bisceglio, G., Zou, F., Pankratz, S., Sando, S. B., Aasly, J. O., Barcikowska, M., et al. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-11 · Cited by 82
Self-citationCarrasquillo, M. M., Belbin, O., Hunter, T. A., Ma, L., Bisceglio, G. D., Zou, F., Crook, J. E., Pankratz, V. S., Sando, S. B., Aasly, J. O., et al. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-54 · Cited by 82
Self-citationFan, J., Tao, W., Li, X., Li, H., Zhang, J., Wei, D., Chen, Y., & Zhang, Z. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051177 · Cited by 87
Apolipoprotein E 2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort
Berge, G., Sando, S. B., Rongve, A., Aarsland, D., & White, L. R. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-307228 · Cited by 79
Self-citationMidlife predictors of Alzheimer's disease
Bendlin, B. B., Carlsson, C. M., Gleason, C. E., Johnson, S. C., Sodhi, A., Gallagher, C. L., Puglielli, L., Engelman, C. D., Ries, M. L., Xu, G., et al. (2009) · Maturitas · doi:10.1016/j.maturitas.2009.12.014 · Cited by 81
Detecting At-Risk Alzheimer’s Disease Cases
Fladby, T., Pålhaugen, L., Selnes, P., Waterloo, K. K., Bråthen, G., Hessen, E., Almdahl, I. S., Arntzen, K. A., Auning, E., Eliassen, C. F., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170231 · Cited by 77
Self-citationThe Role of Genetics in Advancing Precision Medicine for Alzheimer’s Disease—A Narrative Review
Freudenberg‐Hua, Y., Li, W., & Davies, P. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00108 · Cited by 80
D’Cunha, N. M., Georgousopoulou, E. N., Dadigamuwage, L., Kellett, J., Panagiotakos, D. B., Thomas, J., McKune, A. J., Mellor, D. D., & Naumovski, N. (2018) · British Journal of Nutrition · doi:10.1017/s0007114517003452 · Cited by 68
ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels
Steward, A., Biel, D., Dewenter, A., Roemer, S., Wagner, F., Dehsarvi, A., Rathore, S., Otero Svaldi, D., Higgins, I., Brendel, M., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.4038 · Cited by 67
Cardiovascular health, genetic risk, and risk of dementia in the Framingham Heart Study
Peloso, G. M., Beiser, A., Satizábal, C. L., Xanthakis, V., Vasan, R. S., Pase, M. P., DeStefano, A. L., & Seshadri, S. S. (2020) · Neurology · doi:10.1212/wnl.0000000000010306 · Cited by 70
Moon, W., Lim, C., Ha, I. H., Kim, Y., Moon, Y., Kim, H.-J., & Han, S. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20952012 · Cited by 67
Fehér, Á., Juhász, A., Rimanóczy, Á., Kalman, J. L., & Janka, Z. (2009) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318199dd7d · Cited by 69
Fan, L., Tzen, K., Chen, Y., Chen, T., Lai, Y., Yen, R., Huang, Y.-Y., Shiue, C., Yang, S., & Chiu, M. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00175 · Cited by 64
Xiao, Q., Liu, Z.-J., Tao, S., Sun, Y.-M., Jiang, D., Li, H., Chen, H., Liu, X., Lapin, B. R., Wang, C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6271 · Cited by 61
Apolipoprotein E polymorphism in cerebrovascular & coronary heart diseases.
Shajith Anoop, S., Misra, A., Meena, K., & Luthra, K. (2010) · PubMed · Cited by 60
Replication of BIN1 Association with Alzheimer's Disease and Evaluation of Genetic Interactions
Carrasquillo, M. M., Belbin, O., Hunter, T. A., Ma, L., Bisceglio, G. D., Zou, F., Crook, J. E., Pankratz, V. S., Sando, S. B., Aasly, J. O., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101932 · Cited by 60
Self-citationHuntington’s Disease: Relationship Between Phenotype and Genotype
Sun, Y., Zhang, Y.-B., & Wu, Z. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9662-8 · Cited by 60
Age‐dependent effects of APOE ε4 in preclinical Alzheimer's disease
Bonham, L. W., Geier, E. G., Fan, C. C., Leong, J. K., Besser, L. M., Kukull, W. A., Kornak, J., Andreassen, O. A., Schellenberg, G. D., Rosen, H. J., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.333 · Cited by 65
Aβ amyloid, cognition, and APOE genotype in healthy older adults
Lim, Y. Y., Ellis, K. A., Ames, D. J., Darby, D., Harrington, K., Martins, R. N., Masters, C. L., Rowe, C. C., Savage, G. R., Szoeke, C. E. I., et al. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.07.004 · Cited by 64
Genomics of Dementia:APOE- andCYP2D6-Related Pharmacogenetics
Cacabelos, R., Martínez, R., Fernández‐Novoa, L., Carril, J. C., Lombardi, V., Carrera, I., Corzo, L., Tellado, I., Leszek, J., McKay, A., et al. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/518901 · Cited by 55
Area-Gomez, E., Larrea, D., Pera, M., Agrawal, R. R., Guilfoyle, D. N., Pirhaji, L., Shannon, K., Arain, H. A., Ashok, A., Chen, Q., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-61142-8 · Cited by 55
Yu, L., Boyle, P. A., Wilson, R. S., Segawa, E., Leurgans, S. E., Jager, P. L. D., & Bennett, D. A. (2012) · Neuroepidemiology · doi:10.1159/000339365 · Cited by 54
Wang, Y., Du, Y., Li, J., & Qiu, C. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00129 · Cited by 54
Age-dependent effect of APOE and polygenic component on Alzheimer's disease
Bellou, E., Baker, E. A., Leonenko, G., Bracher‐Smith, M., Daunt, P., Menzies, G. E., Williams, J. H., & Escott‐Price, V. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.04.024 · Cited by 51
Molecular Insight into the Therapeutic Promise of TargetingAPOE4for Alzheimer’s Disease
Mamun, A. A., Uddin, M. S., Bashar, M. F. B., Zaman, S., Begum, Y., Bulbul, I. J., Islam, M. S., Sarwar, M. S., Mathew, B., Amran, M. S., et al. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/5086250 · Cited by 54
Roberts, J. A., Varma, V. R., An, Y., Varma, S., Candia, J., Fantoni, G., Tiwari, V., Anerillas, C., Williamson, A., Saito, A., et al. (2021) · Science Advances · doi:10.1126/sciadv.abi8178 · Cited by 49
Sex Differences in Cognition Across Aging
Lee, B. H., Richard, J. E., de leon, R. G., Yagi, S., & Galea, L. A. M. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_309 · Cited by 59
Reeve, E. H., Barnes, J. N., Moir, M. E., & Walker, A. E. (2024) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00592.2023 · Cited by 52
Neurodegenerative diseases: exercising towards neurogenesis and neuroregeneration
Ang, E. (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00025 · Cited by 51
Identification of genetic heterogeneity of Alzheimer's disease across age
Lo, M., Kauppi, K., Fan, C.-C., Sanyal, N., Reas, E. T., Sundar, V. S., Lee, W., Desikan, R. S., McEvoy, L. K., & Chen, C. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.02.022 · Cited by 53
Zhang, X., Yuan, T., Chen, X., Liu, X., Hu, J., & Liu, Z. (2023) · Progress in Lipid Research · doi:10.1016/j.plipres.2023.101256 · Cited by 51
Balhara, N., Devi, M., Balda, A., Phour, M., & Giri, A. (2023) · URINE · doi:10.1016/j.urine.2023.06.001 · Cited by 52
Working Memory in Alzheimer’s Disease and Parkinson’s Disease
Zokaei, N., & Husain, M. (2019) · Current topics in behavioral neurosciences · doi:10.1007/7854_2019_103 · Cited by 52
Choi, D.-H., Kwon, K.-C., Hwang, D.-J., Koo, J., Um, H.-S., Song, H., Kim, J., Jang, Y., & Cho, J. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02335-8 · Cited by 49
Chen, H.-F., Huang, C.-Q., You, C., Wang, Z.-R., & Si-qing, H. (2013) · Archives of Medical Research · doi:10.1016/j.arcmed.2013.01.002 · Cited by 48
Pharmacogenomics and therapeutic strategies for dementia
Cacabelos, R. (2009) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.09.42 · Cited by 48
Evaluation of dietary and lifestyle changes as modifiers of S100β levels in Alzheimer’s disease
D'Cunha, N. M., McKune, A. J., Panagiotakos, D. B., Georgousopoulou, E. N., Thomas, J., Mellor, D. D., & Naumovski, N. (2017) · Nutritional Neuroscience · doi:10.1080/1028415x.2017.1349032 · Cited by 47
Stem cell therapy for Alzheimer’s disease: An overview of experimental models and reality
Qin, C., Wang, K., Zhang, L., & Bai, L. (2022) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12207 · Cited by 49
Cacabelos, R., Fernández‐Novoa, L., Martínez‐Bouza, R., McKay, A., Carril, J. C., Lombardi, V., Corzo, L., Carrera, I., Tellado, I., Nebril, L., et al. (2010) · Pharmaceuticals · doi:10.3390/ph3103040 · Cited by 47
NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load
Pohlkamp, T., Xian, X., Wong, C. H., Durakoglugil, M. S., Werthmann, G. C., Saido, T. C., Evers, B. M., White, C. L., Connor, J., Hammer, R. E., et al. (2021) · eLife · doi:10.7554/elife.72034 · Cited by 46
CD36 gene polymorphism is associated with Alzheimer's disease
Šerý, O., Janoutová, J., Ewerlingová, L., Hálová, A., Lochman, J., Janout, V., Khan, N. A., & Balcar, V. J. (2017) · Biochimie · doi:10.1016/j.biochi.2017.01.009 · Cited by 44
Sandau, U. S., McFarland, T. J., Smith, S. J., Galasko, D. R., Quinn, J. F., & Saugstad, J. A. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.864022 · Cited by 46
He, L., Loika, Y., Park, Y., Bennett, D. A., Kellis, M., Kulminski, A. M., & Initiative, A. D. N. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01263-4 · Cited by 41
Tang, X., Initiative, A. D. N., Holland, D., Dale, A. M., & Miller, M. I. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150262 · Cited by 42
Hydromorphone for neuropathic pain in adults
Stannard, C., Gaskell, H., Derry, S., Aldington, D. J., Cole, P., Cooper, T. E., Knaggs, R., Wiffen, P. J., & Moore, R. A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011604.pub2 · Cited by 41
Abbas, K., Mustafa, M., Alam, M., Habib, S., Ahmad, W., Adnan, M., Hassan, M. I., & Usmani, N. (2025) · Neurogenetics · doi:10.1007/s10048-025-00821-y · Cited by 48
Abushakra, S. R., Porsteinsson, A. P., Sabbagh, M. N., Bracoud, L., Schaerer, J., Power, A., Hey, J. A., Scott, D., Suhy, J., Tolar, M., et al. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12117 · Cited by 40
Multi-functional role of apolipoprotein E in neurodegenerative diseases
Islam, S., Noorani, A. A., Sun, Y., Michikawa, M., & Zou, K. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1535280 · Cited by 43
Fentanyl for neuropathic pain in adults
Derry, S., Stannard, C., Cole, P., Wiffen, P. J., Knaggs, R., Aldington, D. J., & Moore, R. A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011605.pub2 · Cited by 39
The APOE ε2 Allele Increases the Risk of Earlier Age at Onset in Machado-Joseph Disease
Bettencourt, C. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.636 · Cited by 41
Eldholm, R. S., Persson, K., Barca, M. L., Knapskog, A., Cavallin, L., Engedal, K., Selbæk, G., Skovlund, E., & Saltvedt, I. T. (2018) · BMC Geriatrics · doi:10.1186/s12877-018-0813-4 · Cited by 39
Self-citationJohnson, D. A., Lane, J. M., Wang, R., Reid, M., Djonlagic, I. E., Fitzpatrick, A. L., Rapp, S. R., Charles, L. E., O'Hara, R. M., Saxena, R., et al. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201701-052oc · Cited by 39
Thrush, K., Bennett, D. A., Gaiteri, C., Horvath, S., van Dyck, C. H., Higgins‐Chen, A., & Levine, M. E. (2022) · Aging · doi:10.18632/aging.204196 · Cited by 38
Trends of mortality from Alzheimer's disease in the European Union, 1994–2013
Niu, H., Álvarez‐Álvarez, I., Guillén‐Grima, F., Al-Rahamneh, M. J., & Aguinaga-Ontoso, I. (2017) · European Journal of Neurology · doi:10.1111/ene.13302 · Cited by 42
Buprenorphine for neuropathic pain in adults
Wiffen, P. J., Derry, S., Moore, A., Stannard, C., Aldington, D. J., Cole, P., & Knaggs, R. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011603.pub2 · Cited by 37
Apolipoprotein E isoform-dependent effects on the processing of Alzheimer's amyloid-β
Chai, A. B., Lam, H. H. J., Kockx, M., & Gelissen, I. C. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.158980 · Cited by 41
Genetic Factors Affecting Late-Onset Alzheimer’s Disease Susceptibility
Rezazadeh, M., Khorrami, A., Yeghaneh, T., Talebi, M., Kiani, S. J., Heshmati, Y., & Gharesouran, J. (2015) · NeuroMolecular Medicine · doi:10.1007/s12017-015-8376-4 · Cited by 37
López-López, A., Gelpí, E., Lopategui, D. M., & Vidal-Taboada, J. M. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0489-3 · Cited by 35
Apolipoprotein E Genotypes, Age, Race, and Cognitive Decline in a Population Sample
Rajan, K. B., Barnes, L. L., Wilson, R. S., Weuve, J., McAninch, E. A., & Evans, D. A. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15727 · Cited by 41
Blackman, J., Love, S., Sinclair, L. I., Cain, R., & Coulthard, E. J. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-00992-y · Cited by 37
Marine Neurotoxins’ Effects on Environmental and Human Health: An OMICS Overview
Guillotin, S., & Delcourt, N. (2021) · Marine Drugs · doi:10.3390/md20010018 · Cited by 35
Deal, S. L., & Yamamoto, S. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2018.00700 · Cited by 36
APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer’s Disease
Waring, J. F., Tang, Q., Robieson, W., King, D. P., Das, U., Dubow, J. S., Dutta, S., Marek, G. J., & Gault, L. M. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142589 · Cited by 35
Enrichment factors for clinical trials in mild‐to‐moderate Alzheimer's disease
Ballard, C. G., Atri, A., Boneva, N., Cummings, J. L., Frölich, L., Molinuevo, J. L., Tariot, P. N., & Rakêt, L. L. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.04.001 · Cited by 33
Metadata
- Authors
- Sando, S. B., Melquist, S., Cannon, A., Hutton, M. L., Sletvold, O., Saltvedt, I., White, L. R., Lydersen, S., & Aasly, J. O.
- Affiliations
- Norwegian University of Science and Technology (NO)
- Mayo Clinic (US)
- Corresponding author
- Sando, Sigrid B
- Venue
- BMC Neurology
- Published
- 2008-04-16
- Volume
- 8
- Issue
- 1
- Pages
- 9-9
- ISSN
- 1471-2377 (ISSN-L)
- PMC
- PMC2375917
- OpenAlex
- W1972488785
- Cited by
- 261
- References
- 39
- Citations by year
- 2026: 11 · 2025: 24 · 2024: 21 · 2023: 12 · 2022: 22 · 2021: 20 · 2020: 13 · 2019: 12 · 2018: 17 · 2017: 15 · 2016: 13 · 2015: 16 · 2014: 10 · 2013: 10 · 2012: 11
- FWCI
- 7.94
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- BMC Neurology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- BIBSYS Brage (BIBSYS (Norway)) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- NORA - Norwegian Open Research Archives (submittedVersion, cc-by)
- Funders
- Mayo Foundation for Medical Education and Research (AG17216)
- Norges Forskningsråd (153487/V50)
- National Institutes of Health (AG17216)
- National Institute on Aging (P01-AG-17216, F32AG024030, AG 24030, P01AG017216)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- Alzheimer's disease, APOE ε4, apolipoprotein E, late-onset Alzheimer's disease, age of onset, genetic risk factors, APOE ε2 allele, allele frequency, early-onset Alzheimer's disease, dose-dependent effects
- MeSH terms
- Aged, Aged, 80 and over, Alleles, Alzheimer Disease, Female, Gene Frequency, Humans, Male, Norway, Risk Factors, Odds Ratio, Case-Control Studies, Age of Onset, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
